Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 15, 2025 07:14 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

First patient in SXTP’s relapsing babesiosis study tested negative post-tafenoquine; FDA Breakthrough request filed, Type B meeting planned 2026.
October 09, 2025 07:04 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

60 Degrees Pharma unveils “B-FREE” Phase 2 trial for chronic babesiosis, engaging patients in naming and supporting Lyme research groups.
August 13, 2025 16:14 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

60 Degrees Pharma (Nasdaq: SXTP) Q2 2025: Supply issue cut revenue, profits rose from cash-pay sales; $1.97M cash extends runway to Mar 2026.
July 17, 2025 08:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

60 Degrees and Tulane to study tafenoquine against Lyme and Bartonella bacteria, part of the “3Bs” common in tick-borne illness co-infections.
July 16, 2025 16:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

60 Degrees closes $5M public offering with up to $5M more from short-term warrants; funds support working capital and infectious disease R&D.
July 15, 2025 09:10 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

60 Degrees Pharma (SXTP) prices $5M public offering with potential $5M from warrant exercise; funds to support working capital and corporate purposes.
July 15, 2025 07:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

60 Degrees sets human babesiosis TAM for ARAKODA at $245M annually, $1.1B total through 2035; NDA planned for 2026 pending trial data.
June 04, 2025 08:56 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

60 Degrees launches 8-count ARAKODA® bottles, offering weekly malaria protection for short trips. Now available via major retail pharmacies.
June 03, 2025 08:49 ET | Source: Sixty Degrees Pharmaceuticals

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

Insurance claims show U.S. babesiosis incidence may be 10x CDC estimates; 60 Degrees links chronic fatigue and plans 2026 NDA for tafenoquine treatment.
April 08, 2025 08:31 ET | Source: Sixty Degrees Pharmaceuticals

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited treatments.